FIORICET W/ CODEINE (butalbital, acetaminophen, caffeine, and codeine phosphate) by Teva is butalbital, a barbiturate, is a gaba a receptor agonist and may inhibit excitatory ampa receptors. Approved for the symptom complex of tension (or muscle contraction) headache, alternative treatments are inadequate, other non-opioid analgesic. First approved in 1992.
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
Fioricet w/ Codeine is an oral fixed-dose combination of butalbital (barbiturate), acetaminophen, caffeine, and codeine phosphate (opioid) indicated for tension headaches when alternative treatments are inadequate. The product works through multiple mechanisms: butalbital acts as a GABA-A receptor agonist for CNS depression, acetaminophen provides central analgesic effects, caffeine antagonizes adenosine receptors as a CNS stimulant, and codeine acts as a mu-opioid receptor agonist.
Product faces approaching loss of exclusivity with moderate competitive pressure (30); brand teams should expect declining revenue and a right-sizing of commercial infrastructure.
Butalbital, a barbiturate, is a GABA A receptor agonist and may inhibit excitatory AMPA receptors. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. Caffeine is a methylxanthine and CNS stimulant. The exact mechanism…
Barbiturate
Worked on FIORICET W/ CODEINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Fioricet w/ Codeine offers limited career growth; roles focus on managed decline, compliance, and defending market position against generics rather than innovation or expansion. This is a legacy product suitable for early-career roles seeking operational experience or specialists managing opioid-containing product portfolios in a restrictive regulatory environment.